Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Nat Rev Clin Oncol. 2012 Feb 28;9(4):194-6. doi: 10.1038/nrclinonc.2012.28.
No abstract available

Publication types

  • News

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Clinical Trials as Topic
  • Female
  • Humans
  • Ovarian Neoplasms / drug therapy*
  • Prognosis
  • Standard of Care*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab